Gilead didn't seem to be interested in DEP® Remdesivir or certainly didn't proceed in the last 2 years if they were since JF spruiked about it, so I wonder with this new announcement today if any other DEP® products for oncology will interest them ?
https://www.fiercepharma.com/pharma...-seeing-33-revenue-coming-oncology-drugs-2030
Gilead, after setbacks, aims to pull a third of its revenue from oncology business by 2030
By Kevin DunleavyApr 19, 2022 05:15am
AGM 5 months ago, page-25
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.8¢ |
Change
0.001(1.03%) |
Mkt cap ! $40.97M | |||
| Open | High | Low | Value | Volume |
| 9.7¢ | 9.9¢ | 9.7¢ | $44.76K | 455.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 824859 | 9.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 121525 | 5 |
View Market Depth
| Last trade - 16.10pm 04/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |